Quest Diagnostics (DGX) Tops Q3 EPS by 2c; Narrows FY16 Outlook

October 20, 2016 6:46 AM EDT

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

Quest Diagnostics (NYSE: DGX) reported Q3 EPS of $1.37, $0.02 better than the analyst estimate of $1.35. Revenue for the quarter came in at $1.89 billion versus the consensus estimate of $1.89 billion.


Quest Diagnostics sees FY2016 EPS of $5.07-$5.12, versus prior guidance of $5.02-$5.17 and the consensus of $5.11. Quest Diagnostics sees FY2016 revenue of $7.51 billion, versus prior guidance of $7.47-7.54 billion and the consensus of $7.52 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities


Add Your Comment